VEGFA and ovarian carcinoma: Starting from previously published data indicating that anti-VEGF therapy decreased glucose levels in subcutaneous xenografts of ovarian cancer cell lines [12], we subsequently investigated whether short-term treatment with the antiangiogenic drug bevacizumab altered glucose concentration in the PDOVCA’s ascites in vivo.